MEIS3P2: A Potential Drug Target Or Biomarker (G257468)

Target Name: MEIS3P2

NCBI ID: G257468

MEIS3P2

Other Name(s): Meis homeobox 3 pseudogene 2

MEIS3P2: A Potential Drug Target Or Biomarker

MEIS3P2, also known as Meis homeobox 3 pseudogene 2, is a gene that is located on chromosome 16 and encodes for a protein known as MBP2. MBP2 is a transmembrane protein that is involved in the regulation of cell adhesion, as well as the development and progression of various diseases, including cancer.

In recent years, researchers have been increasingly interested in MEIS3P2 as a potential drug target or biomarker. This is because the gene has been shown to be involved in the development of several types of cancer, including breast, ovarian, and prostate cancer. Additionally, studies have also suggested that MEIS3P2 may be involved in the development of other diseases, such as neurodegenerative disorders and autoimmune diseases.

One of the key reasons why researchers are interested in MEIS3P2 is because of its location on chromosome 16. This is why it is often referred to as a \"hot spot\" gene for cancer. Studies have shown that people with certain genetic variations, known as \"variants,\" are at an increased risk of developing cancer. MEIS3P2 is one of these variants, and researchers are seeking to understand how it contributes to the development of cancer.

In addition to its potential as a drug target or biomarker, MEIS3P2 is also of interest to researchers because of its role in cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs. This is important for many types of biological processes, including the development and maintenance of tissues and organs, and the regulation of signaling pathways.

Research has shown that MEIS3P2 plays a key role in regulating cell adhesion in various cell types. For example, studies have shown that MEIS3P2 is involved in the regulation of cell-cell adhesion, as well as cell-extracellular matrix (ECM) adhesion. This means that MEIS3P2 is involved in the stickiness of cells to other cells and to their surrounding environment.

Another potential drug target for MEIS3P2 is its role in the development of cancer. Studies have shown that people with certain genetic variations, known as \"variants,\" are at an increased risk of developing cancer. MEIS3P2 is one of these variants, and researchers are seeking to understand how it contributes to the development of cancer.

One of the key things that researchers are interested in studying about MEIS3P2 is its potential as a biomarker. This is because the gene has been shown to be involved in the regulation of various signaling pathways, including the regulation of cell growth and differentiation. This means that researchers may be able to use MEIS3P2 as a biomarker to predict the development of certain diseases, such as cancer.

In addition to its potential as a drug target or biomarker, MEIS3P2 is also of interest to researchers because of its location on chromosome 16. This is why it is often referred to as a \"hot spot\" gene for cancer. Studies have shown that people with certain genetic variations, known as \"variants,\" are at an increased risk of developing cancer. MEIS3P2 is one of these variants, and researchers are seeking to understand how it contributes to the development of cancer.

Overall, MEIS3P2 is a gene that is of interest to researchers due to its location on chromosome 16 and its involvement in the regulation of cell adhesion and the development of cancer. Further studies are needed to fully understand its role in these processes and its potential as a drug target or biomarker.

Protein Name: Meis Homeobox 3 Pseudogene 2

The "MEIS3P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MEIS3P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets